【摘要】 目的 驗證臨床藥師對外科預防使用抗菌藥物進行干預的效果。 方法 以臨床藥師督查記錄數據為基礎，將2010年1-3月238份病歷設為非干預組，2010年10—12月240份病歷設為干預組，建立評價標準，進行回顧性匯總、分析。 結果 通過干預，抗菌藥物使用率從干預前的100%下降為77.08%（χ2=63.633，P=0.000），抗菌藥物聯用情況減少（χ2=53.712，P=0.000），用藥時機和用藥療程有了較大改善，抗菌藥物費用下降（t=-5.235，P=0.000），住院醫療費用降低（t’=-12.280，P=0.000），住院天數減少（t=-5.071，P=0.000）。 結論 臨床藥師通過實施合理用藥干預對促進醫院安全、有效、經濟使用抗菌藥物起到了積極作用。【Abstract】 Objective To verify the effect of clinical pharmacists’ intervention in antibiotics used for Type I incision surgical prevention. Methods Based on the supervision and inspection recording data of clinical pharmacists, we arranged 238 medical records in the first quarter of 2010 as non-intervened group and 240 medical records in the fourth quarter of 2010 as intervened group, and then established evaluation criteria and conducted a retrospective study for analysis. Results Through intervention, the rate of using antibiotics decreased from the previous 100% to 77.08% (χ2=63.633, P=0.000), the use of combined antibiotics also decreased (χ2=53.712, P=0.000), the time of course of using antibiotics improved, medical expenses of the antibiotics were reduced (t=-5.235, P=0.000), hospitalization cost decreased (t=-12.280, P=0.000), and hospital stay was shortened (t=-5.071, P=0.000). Conclusion Clinical pharmacists’ intervention in rational use of drugs play a positive role in contribution to a safe, effective and economical application of antibiotics.
Multidrug-resistant bacterial infection is one of the important causes of death in intensive care unit (ICU) patients, which can significantly increase the length of hospital stay and treatment costs for ICU patients. At present, domestic scholars have paid less attention to hospital-acquired multidrug-resistant bacterial infection in ICU patients. This article summarizes the clinical manifestations, risk factors, and prevention and control measures of hospital-acquired multidrug-resistant bacterial infection in ICU patients, aiming to improve the understanding of medical staff on the situation of hospital-acquired multidrug-resistant bacterial infection in ICU and promote the development of hospital infection prevention and control.